Chimeric Therapeutics (ASX: CHM) achieves significant progress with latest brain cancer treatment trial (w/ Jennifer Chow)
Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the successful results of a new brain cancer (glioblastoma) treatment trial. The phase 1A trial achieved a 55% disease control rate (DCR) in patients treated with its CLTX CAR T solution, well above historical disease control rates. Under that trial two patients exceeded a survival period of 14 months, while three patients remained alive and in follow up. This is in direct comp...
